Pediatric postural orthostatic tachycardia syndrome: From mechanisms to individualized management

Abstract

Postural orthostatic tachycardia syndrome (POTS) represents chronic orthostatic intolerance. Patients usually suffer from presyncopal symptoms, such as lightheadedness, headache, blurred vision, and fatigue. Central hypovolemia, peripheral vascular dysfunction, and a hyperadrenergic state may contribute to the pathogenesis of POTS. It is necessary to comprehensively assess the clinical characteristics, physiological changes, and biochemical markers to select an appropriate therapy. Since the introduction of the concept of individualized treatment for POTS, great progress has been made in the field.

Keywords

mechanism / postural orthostatic tachycardia syndrome (POTS) / treatment

References

[1] ProbstMA, Kanzaria HK, GbedemahM, RichardsonLD, SunBC. National trends in resource utilization associated with ED visits for Syncope. Am J Emerg Med. 2015; 33(8):998-1001.

[2] ChenL, LiX-Y, ToddO, Wang C, JinH-F, DuJ-B. A clinical manifestation-based prediction of haemodynamic patterns of orthostatic intolerance in children: a multi-centre study. Cardiol Young. 2014; 24(4):649-653.

[3] StewartJM, BorisJR, ChelimskyG, et al. Pediatric disorders of orthostatic intolerance. Pediatrics. 2018; 141(1):e20171673.

[4] LiaoY, DuJ-B. Pathophysiology and individualized management of vasovagal Syncope and postural tachycardia syndrome in children and adolescents: an update. Neurosci Bull. 2020; 36(6):667-681.

[5] XuW-R, JinH-F, DuJ-B. Pathogenesis and individualized treatment for postural tachycardia syndrome in children. Chin Med J (Engl). 2016; 129(18):2241-2245.

[6] ChenL, WangL, SunJ-H, et al. Midodrine hydrochloride is effective in the treatment of children with postural orthostatic tachycardia syndrome. Circ J. 2011; 75(4):927-931.

[7] FuQ, LevineBD. Exercise and non-pharmacological treatment of POTS. Auton Neurosci. 2018; 215:20-27.

[8] LuW-X, YanH, WuS, et al. Electrocardiography-derived predictors for therapeutic response to treatment in children with postural tachycardia syndrome. J Pediatr. 2016; 176:128-133.

[9] LiH-X, LiaoY, WangY-L, et al. Baroreflex sensitivity predicts short-term outcome of postural tachycardia syndrome in children. PLoS One. 2016; 11(12):e0167525.

[10] LuW-X, YanH, WuS, XuW-R, JinH-F, Du J-B. Hemocytometric measures predict the efficacy of oral rehydration for children with postural tachycardia syndrome. J Pediatr. 2017; 187:220-224.

[11] LinJ, LiuP, WangY-L, et al. Evaluation of the changes in heart rate during head-up test predicting the efficacy of oral rehydration salts on postural tachycardia syndrome in children (In Chinese). Chin J Pediatr. 2015; 53(1):25-29.

[12] McLeanRM. Measuring population sodium intake: a review of methods. Nutrients. 2014; 6(11):4651-4662.

[13] ZhangQ-Y, LiaoY, TangC-S, Du J-B, JinH-F. Twenty-four-hour urinary sodium excretion and postural orthostatic tachycardia syndrome. J Pediatr. 2012; 161(2):281-284.

[14] LiH-X, WangY-L, LiuP, et al. Body mass index (BMI) is associated with the therapeutic response to oral rehydration solution in children with postural tachycardia syndrome. Pediatr Cardiol. 2016; 37(7):1313-1318.

[15] ZhangQ-Y, ChenX, LiJ-W, Du J-B. Orthostatic plasma norepinephrine level as a predictor for therapeutic response to metoprolol in children with postural tachycardia syndrome. J Transl Med. 2014; 12(1):249.

[16] LinJ, HanZ-H, LiH-X, et al. Plasma C-type natriuretic peptide as a predictor for therapeutic response to metoprolol in children with postural tachycardia syndrome. PLoS One. 2015; 10(3):e0121913.

[17] ZhaoJ, DuS-X, YangJ-Y, et al. Usefulness of plasma copeptin as a biomarker to predict the therapeutic effectiveness of metoprolol for postural tachycardia syndrome in children. Am J Cardiol. 2014; 114(4):601-605.

[18] WangS, ZouR-M, CaiH, et al. Heart rate and heart rate difference predicted the efficacy of metoprolol on postural tachycardia syndrome in children and adolescents. J Pediatr. 2020; 224:110-114.

[19] XuB-W, ZhangQ-Y, LiX-Y, et al. A predictive model of response to metoprolol in children and adolescents with postural tachycardia syndrome. World J Pediatr. 2023; 19(4):390-400.

[20] ZhangF-W, LiX-Y, OchsT, et al. Midregional pro-adrenomedullin as a predictor for therapeutic response to midodrine hydrochloride in children with postural orthostatic tachycardia syndrome. J Am Coll Cardiol. 2012; 60(4):315-320.

[21] ZhaoJ, TangC-S, JinH-F, Du J-B. Plasma copeptin and therapeutic effectiveness of midodrine hydrochloride on postural tachycardia syndrome in children. J Pediatr. 2014; 165(2):290-294.e1.

[22] YangJ-Y, ZhaoJ, DuS-X, et al. Postural orthostatic tachycardia syndrome with increased erythrocytic hydrogen sulfide and response to midodrine hydrochloride. J Pediatr. 2013; 163(4):1169-1173.e2.

[23] DengW-J, LiuY-L, LiuAD, et al. Difference between supine and upright blood pressure associates to the efficacy of midodrine on postural orthostatic tachycardia syndrome (POTS) in children. Pediatr Cardiol. 2014; 35(4):719-725.

[24] LiaoY, YangJ-Y, ZhangF-W, et al. Flow-mediated vasodilation as a predictor of therapeutic response to midodrine hydrochloride in children with postural orthostatic tachycardia syndrome. Am J Cardiol. 2013; 112(6):816-820.

RIGHTS & PERMISSIONS

2024 The Author(s). Pediatric Discovery published by John Wiley & Sons Australia, Ltd on behalf of Children’s Hospital of Chongqing Medical University.